Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

Area of Science:

• Immunotherapy
• Melanoma Research
• Oncology

Background:

• Metastatic melanoma patients often progress on ipilimumab.
• Subsequent anti-programmed death-1 (PD-1) therapy can be beneficial.
• Predictors of response to anti-PD-1 after ipilimumab are not well understood.

Purpose of the Study:

• To investigate if ipilimumab progression patterns influence outcomes with subsequent pembrolizumab.
• To determine the association between ipilimumab progression-free survival (PFS) and pembrolizumab response.

Main Methods:

• Retrospective review of 116 metastatic melanoma patients.
• Patients progressed on ipilimumab and received subsequent pembrolizumab.
• Analysis of PFS, objective response rate (ORR), and clinical benefit rate (CBR) with pembrolizumab based on ipilimumab PFS.

Main Results:

• Patients with ipilimumab PFS ≥90 days had superior pembrolizumab outcomes (CBR 66% vs. 46%, P=0.03).
• Prolonged ipilimumab benefit (PFS ≥180 days) correlated with excellent pembrolizumab response (ORR 55%, CBR 80%).
• Ipilimumab PFS independently predicted pembrolizumab response (OR 1.22, 95% CI 1.02-1.51).

Conclusions:

• Prolonged PFS on ipilimumab is a significant predictor of favorable outcomes with subsequent pembrolizumab.
• This finding offers valuable prognostic information for managing metastatic melanoma.
• Ipilimumab treatment duration may guide subsequent immunotherapy choices.